# Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules

> **NCT02027662** · PHASE2,PHASE3 · COMPLETED · sponsor: **Fresenius Medical Care Deutschland GmbH** · enrollment: 61 (actual)

## Conditions studied

- Hyperphosphatemia
- Chronic Kidney Disease

## Interventions

- **DRUG:** Osvaren Granules
- **DRUG:** Osvaren film-coated tablets

## Key facts

- **NCT ID:** NCT02027662
- **Lead sponsor:** Fresenius Medical Care Deutschland GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-04
- **Final completion:** 2015-06
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2015-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02027662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02027662, "Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT02027662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*